Finance outlook india logo
Home News Exclusive Expert's Viewpoint Corporate Startup Fintech Personal Magazine About Us Budget'26 Budget'24
  • Budget'25 Budget'24
    • Home
    • News
    Ambuja Cements Q4 Results Net Profit Declines 9 percent to Rs 956 Crore Revenue Rises 12 percent

    Ambuja Cements Q4 Results: Net Profit Slips 9% to Rs 956 Cr, Revenue Rises 12%


    Finance Outlook India Team | Tuesday, 29 April 2025

    Ambuja Cements Ltd reported an 8.98% year-on-year (YoY) drop in its consolidated net profit for the fourth quarter ending March 31, 2025 (Q4 FY25). The profit for the three months under review decreased from Rs 1,050.58 crore in Q4 FY24 to Rs 956.27 crore.

    However, compared to the same period last year, the Adani Group's operating revenue climbed by 11.58 percent to Rs 9,802.47 crore from Rs 8,785.28 crore. At Rs 8,821.70 crore, total expenses increased 13.86 percent year over year.

    A dividend of Rs 2 per share has been recommended by the board of directors of the nation's second-largest cement manufacturer. "For the fiscal year 2024–2025, the company has set Friday, June 13, 2025, as the 'Record Date' to ascertain the members' entitlement to a dividend of Rs 2 per equity share with a face value of Rs 2 each fully paid up. Subject to any applicable tax deduction at source, the dividend will be paid on or after July 1, 2025, if declared by shareholders at the next AGM," Ambuja said.

    Ambuja was down 1.88 percent at Rs 534.80. At this price, the counter has fallen 6.99% in the last month. It saw high trading volume on the BSE, with approximately 4.86 lakh shares changing hands at the time of writing this story. The figure exceeded the two-week average volume of 1.78 lakh shares. Turnover on the counter was Rs 26.47 crore, with a market capitalisation (m-cap) of Rs 1,31,777.11 crore.

    Technically, the stock fell below the 5-day, 10-day, 20-day, and 200-day simple moving averages (SMAs), but it rose above the 30-day, 50-day, 100-day, and 150-day SMAs. The 14-day relative strength index (RSI) stood at 46.16. A level less than 30 is considered oversold, and a value greater than 70 is considered overbought.

    The stock's price-to-earnings (P/E) ratio is 39.19, with a price-to-book (P/B) value of 2.87. Earnings per share (EPS) was 13.65, with a return on equity (ROE) of 7.32. According to Trendlyne data, Ambuja's one-year beta is 1.65, indicating high volatility.

    As of March 2025, promoters owned 67.57 percent of the company.



    Read More:

    Bajaj Broking Rides T20 Buzz with ‘Seedhi Simple Investing’ Campaign

    OnMobile Posts Q3 FY26 Results & Appointment of Manoranjan Mohapatra

    KNOWLEDGE DECK

    Most Viewed

    • The Economic Impact of India-Pakistan War: A Detailed Analysis

    • Why Financial Literacy Matters More Than Ever for Today's Youth

    • Prominent Financial Advisors in India to Partner With

    • Rags to Riches: The Top 6 Indian Entrepreneurs' Motivational Tales of Success

    • Navigating Financial Disruption With Future Proof Financial Service Deliverability

    • India's Rs 31 Lakh Cr Green Push: Building the Foundation of a Net-Zero Future

    • Wakhariya & Wakhariya: Facilitating International Legal Processes across Diverse Domains

    • Aligning Financial Strategies with Sustainable Business Goals

    • The Top 5 Highest-paid Actors in India - 2024

    • Central Government Proposes Tax on Agricultural Water Usage

    • Carpediem Capital Invests INR 100 Crore, CorporatEdge to Deploy INR 350 Crore in the next 3 Years

    • EPFO Registers All-Time High Member Addition of 20.06 Lakh in May 2025

    • Unearthing Intricacies of Today and Beyond in the Indian Insurance Sector

    • Expected Correction in Housing Prices to Revive Sales in Coming Quarters

    • How to Choose the Right Mutual Fund for your Financial Goals?

    • Future of Corporate Finance: Emerging Trends in Treasury Solutions and Cash Management for MNCs

    • ElasticRun Announces FY24 Financial Results: Key Details

    • Financial Inclusion in Viksit Bharat

    • Abans Financial Services Advises Vaishali Pharma on Strategic Acquisition of Kesar Pharma






    🍪 Do you like Cookies?

    We use cookies to ensure you get the best experience on our website. Read more...

    Copyright © 2026 Finance Outlook India. All rights reserved.   Privacy Policy Terms of Use Blogs Conferences Subscribe WRAPUP’25